Retinoids and fibrinolysis

Area of Science:

• Biochemistry
• Dermatology
• Cardiovascular Research

Background:

• Vitamin A analogues, or retinoids, have shown potential to increase tissue plasminogen activator (t-PA) release in laboratory settings.
• Dermatological therapies often utilize retinoids, necessitating an understanding of their impact on fibrinolytic factors.

Purpose of the Study:

• To reevaluate the in vitro effects of retinoids on endothelial fibrinolytic factors.
• To investigate if therapeutic doses of retinoids enhance endothelial fibrinolytic factor release.
• To assess the safety implications of retinoid therapy on cardiovascular health.

Main Methods:

• In vitro incubation of endothelial cells with retinoic acid.
• Analysis of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in cell supernatant.
• Plasma analysis of t-PA, PAI-1, and von Willebrand factor in patients treated with isotretinoin or etretinate.

Main Results:

• Retinoic acid significantly increased t-PA release from endothelial cells in vitro.
• No concurrent increase in PAI-1 secretion was observed with retinoic acid treatment.
• Patients on isotretinoin or etretinate showed elevated baseline t-PA plasma levels.
• PAI-1 and von Willebrand factor levels remained unchanged in patients undergoing retinoid therapy.

Conclusions:

• Therapeutic doses of retinoids promote chronic augmentation of t-PA secretion.
• Evidence suggests no endothelial cell damage associated with this enhanced t-PA release.
• Findings may influence the interpretation of long-term retinoid therapy safety, particularly concerning cardiovascular risks linked to hyperlipemia.